Updated: 08/26/2021 7:48 PM IS
Mumbai (Maharashtra) [India], Aug 26 (ANI / NewsVoir): Esperer Nutrition has opened its London, UK office to serve the Onco nutrition gap in the UK, Europe and the US markets.
The move is keeping an eye on the UK audience and will be the Nutraceuticals Market of £ 275 billion worldwide and £ 4 billion in the UK. This step also resonates with the renewed focus Nutraceutical industry among others according to the UK Prime Minister’s Task Force on Innovation, Growth and Regulatory Reform (TIGRR) announced in June 2021. The move also means the organization will invest in research and development in the UK and in strategic collaborations with universities and foundations in the field of nutraceuticals for non-communicable diseases.
Raktim Chattopadhyay, Director of Esperer Nutrition UK Ltd. commented: “1,600 children (15 years and under) in the UK are reported to be diagnosed with cancer each year, the most common being leukemia (30%), brain, CNS and intracranial tumors (20% ) and lymphomas (11%). In addition, 28 million male adults in the UK are overweight or obese, fueling a diet-related health crisis with rising rates of NCDs (non-communicable diseases). Our efforts began with the launch of our innovation – DINI Axis (Diet Infection Nutrition Immunity) aims to bridge the gap in malnutrition by relieving some of the symptoms of NCD patients and improving their quality of life. “
Raktim Chattopadhyay, who is also the founder and CEO of Esperer Nutrition (EON) added, “Non-communicable diseases (NCDs) are very difficult to treat with traditional health tactics, but there are innovative interventions that can be effectively implemented to address noncommunicable disease risk factors Nutra research needs to be more actively involved in exploring factors that affect health and lifestyle. “
DINI Axis (Diet-Infection-Nutrition-Immunity) is a research that identifies the interaction metrics between diet and infection risk factors associated with non-communicable diseases (NCDs). DINI Axis validates therapeutic nutritional interventions by modifying immunomodulatory pathways to improve patients’ overall quality of life. All products contain the highest quality authentic nutraceuticals. The products are designed to support and alleviate noncommunicable diseases and related chronic diseases.
Ganesh Kodag, General Manager for the UK and the European Union Business Areas, added: “Our start here is a strategic success. This start is a big step for an aspiring nutraceutical company – Esperer Nutrition. Our start here is in line with the vision of our founder of “Bringing quality of life to all cancer patients worldwide through innovations.” “Patient 1st” is our motto. ”
The organization will invest in necessary research in addition to investing in research and development in collaboration with various foundations, universities, key opinion leaders and actual patients. With the DINI Axis approach, Esperer Nutrition is already developing disease-specific nutraceuticals. The products are researched and developed using very specific high quality, clinically proven ingredients.
The launch is important to the UK population as it holds the promise of a better quality of life based on better nutrition. Given that in the UK, on average, one woman is diagnosed with cancer every three minutes and one woman dies of cancer every seven minutes. Two-thirds of premature deaths in adult males are associated with noncommunicable diseases, of which cancer is the leading cause of death. 28 million adult male adults in the UK are overweight or obese, fueling a diet-related health crisis with rising rates of NCDs (non-communicable diseases) including type 2 diabetes, cardiovascular disease and certain cancers. Prostate cancer is the most common cancer among men in the UK. More than half of the new cancer cases in men each year are prostate, lung or colon cancer.
Esperer Nutrition (EON) is a research-based nutraceutical company pioneering the prevention and treatment of critical diseases through innovative nutritional therapies. The team is committed to advancing the role of nutritional therapies with proven clinical and health benefits. The organization aims to understand, treat, and prevent a range of diseases by using nutrition as a science. With a special focus on onco nutrition, the team offers a 360-degree solution: from disease management (NCDs and others) to nutritional intervention in prevention.
For more information, see: www.esperernutrition.com or write to [email protected].
This story is provided by NewsVoir. ANI assumes no responsibility for the content of this article. (ANI / NewsVoir)